Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$1.80
+2.3%
$1.69
$1.21
$3.81
$44.46M0.68260,159 shs200,139 shs
Inventiva S.A. stock logo
IVA
Inventiva
$3.30
-1.9%
$3.31
$1.53
$4.05
$315.21M0.863,208 shs7,932 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.71
-4.9%
$13.36
$5.22
$27.38
$159.99M0.41142,248 shs113,689 shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$17.09
-1.1%
$13.69
$2.03
$14.36
$160.61M1.1150,104 shs167,843 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.00%0.00%+21.38%-33.33%-4.35%
Inventiva S.A. stock logo
IVA
Inventiva
+8.32%+4.96%-12.98%+7.46%-2.45%
LifeVantage Co. stock logo
LFVN
LifeVantage
+5.61%+0.91%+9.05%-21.72%+77.56%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00%-11.48%+12.13%+4.10%-46.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.6258 of 5 stars
1.00.00.00.00.63.31.3
Inventiva S.A. stock logo
IVA
Inventiva
2.2676 of 5 stars
3.43.00.00.01.91.70.6
LifeVantage Co. stock logo
LFVN
LifeVantage
4.2734 of 5 stars
3.53.01.72.72.31.71.3
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
2.00
Hold$1.67-7.41% Downside
Inventiva S.A. stock logo
IVA
Inventiva
2.80
Moderate Buy$10.40215.63% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50139.97% Upside
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AADI, NLTX, LFVN, and IVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2025
Inventiva S.A. stock logo
IVA
Inventiva
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $9.00
3/28/2025
Inventiva S.A. stock logo
IVA
Inventiva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$25.07M1.77N/AN/A$4.29 per share0.42
Inventiva S.A. stock logo
IVA
Inventiva
$9.20M34.27N/AN/A($0.67) per share-4.92
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.72$0.67 per share19.03$2.38 per share5.34
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)
Inventiva S.A. stock logo
IVA
Inventiva
-$119.51MN/A0.00N/AN/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6922.70N/A3.46%34.29%15.04%N/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A

Latest AADI, NLTX, LFVN, and IVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/18/2025Q4 2024
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$0.30-$0.67-$0.37-$0.67$7.45 million$7.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/AN/AN/AN/AN/A
Inventiva S.A. stock logo
IVA
Inventiva
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.42%N/A26.09%3 Years
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A

Latest AADI, NLTX, LFVN, and IVA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/A
4.89
4.54
Inventiva S.A. stock logo
IVA
Inventiva
N/A
0.59
0.59
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33

Institutional Ownership

CompanyInstitutional Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
52.08%
Inventiva S.A. stock logo
IVA
Inventiva
19.06%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%

Insider Ownership

CompanyInsider Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
37.30%
Inventiva S.A. stock logo
IVA
Inventiva
32.00%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
1.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
4024.70 million15.49 millionOptionable
Inventiva S.A. stock logo
IVA
Inventiva
10095.66 million35.68 millionNot Optionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data

Recent News About These Companies

(NGNE) Proactive Strategies
Neurogene concludes merger deal with Neoleukin Therapeutics
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aadi Bioscience stock logo

Aadi Bioscience NASDAQ:AADI

$1.80 +0.04 (+2.27%)
As of 05/27/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Inventiva stock logo

Inventiva NASDAQ:IVA

$3.30 -0.07 (-1.93%)
Closing price 03:55 PM Eastern
Extended Trading
$3.25 -0.04 (-1.37%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.71 -0.66 (-4.94%)
Closing price 04:00 PM Eastern
Extended Trading
$12.71 0.00 (0.00%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$17.09 -0.19 (-1.10%)
As of 05/27/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.